“Tralokinumab Treatment In Patients With Atopic Dermatitis and Moderate-to-Severe Hand Involvement: Results From the 32-Week Phase 3b ADHAND Trial”. SKIN The Journal of Cutaneous Medicine, vol. 10, no. 2, Mar. 2026, p. s744, https://doi.org/10.25251/ppt8ep84.